S. Aliberti

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

Giovanni Grignani, Lorenzo D’Ambrosio, Ymera Pignochino et al. · The Lancet Oncology · 2018 · 95 citations · Full text

Medicine, Oncology, Surgery +13

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio et al. · Molecular Cancer · 2017 · 71 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour

Lorenzo D’Ambrosio, Erica Palesandro, Paola Boccone et al. · European Journal of Cancer · 2017 · 39 citations

Medicine, Oncology, Gastroenterology +12

Erythrocyte macrocytosis is a rather common, apparently uneventful yet unexplained finding in GIST imatinib (I) chronic therapy

S. Aliberti, Giovanni Grignani, P. Allione et al. · Journal of Clinical Oncology · 2005 · 10 citations

Medicine, Hematology, Oncology +14